| INTRODUC TI ON
Hyperthyroidism affects an estimated 1 in 2000 people annually in Europe. The most common causes of hyperthyroidism include Graves' disease (GD), multinodular goitre (MNG) and toxic nodule.
Appropriate treatment for patients relies on correct diagnosis and is influenced by both the clinical experience of endocrinologists and patients' coexisting comorbidities and preferences. Early and appropriate treatment of hyperthyroidism is important in preventing cardiovascular and metabolic complications such as osteoporosis 1 and thyroid storm 2 and is based on recommendation by specialist bodies such as the British Thyroid Association. 3 The mainstays of treatment include antithyroid drugs, radioiodine therapy and thyroidectomy.
Summary
Aims: A study looking at the distribution, management and outcomes of patients referred to a secondary care endocrine clinic with a diagnosis of hyperthyroidism. Results: Patients (75% female, age range 17-91 years) were treated with thionamides for an average of 295 days. As expected, the majority of patients had Graves Disease (GD) (80%), followed by those with multinodular goitre (MNG) (8.6%), amiodarone-induced hyperthyroidism (6.7%) and toxic nodule (3.7%). Drug-induced remission rates were best seen in patients with GD (43%), and side effects necessitating change in treatment were relatively low (2.5%). In 121 patients who received radioiodine, hypothyroidism occurred in 50% of patients and was commoner in patients with GD (65%) than in those with MNG (22%) and toxic nodule (6.3%).
Conclusions:
This study is only one of a few reporting on the characteristics of patients with hyperthyroidism attending a typical secondary care endocrine clinic.
Whilst we appreciate its limitations, we encourage similar methods of collecting valuable real world data to facilitate conduction of specialist peer review visits in other similar clinic settings.
K E Y W O R D S
diagnosis, radioiodine, thionamides, thyroid 3 In USA, radioiodine is generally considered early on after achieving a euthyroid state with a short course of thionamides. 4 Although patients are often considered to be in remission if they retain a normal thyroid function test (TFT) 1 year after discontinuation of antithyroid drugs, we used a 6-month cut-off in our series. The remission rate varies considerably between geographical areas. A European study showed a 50%-60% remission rate after 5-6 years after discontinuation of treatment, whereas a US based study demonstrated only a 20%-30% remission at 18 months.
| Antithyroid medications (Thionamides)

5
Lower remission rates have been described in men, younger patients, smokers and those with large goitres or elevated TSH receptor antibodies (TRAB) at diagnosis.
In patients with toxic MNG, definitive treatment such as radioiodine or surgery is generally considered early as prolonged treatment with thionamides rarely offers cure. 6 Thionamides are generally well tolerated and agranulocytosis occurs in <3% of patients. 7 Milder and commoner side effects include skin rashes, pruritus and hair loss (commoner with CMZ), GI symptoms, and deranged LFTs (commoner with PTU), and occur in about 10% of patients. 
| Radioiodine therapy
Radioiodine (usual prescribed dose range 350-600 MBq) has been used to treat hyperthyroidism for more than seven decades and works by inducing damage of DNA leading to death of thyroid cells.
It is usually well tolerated and severe complications are rare. The most common complication is permanent hypothyroidism (40%-80% of subjects) and may occur from 4 to 16 weeks after treatment.
Rarer side effects include sore throat and radiation thyroiditis, but there is no convincing evidence for increased cancer risk. 9 It is not recommended for patients with active thyroid eye disease (TED) and is contraindicated in pregnancy and in those in prolonged contact with children (eg, young mothers). Some patients, such as those with large goitres, may need repeated (higher dose) treatments to achieve euthyroidism. 10 In unusual cases refractory to more than three administrations of radioiodine, surgery should be considered.
| Thyroidectomy
This would be the preferred option where drug treatments or radioiodine have been ineffective, or are contraindicated. Such scenarios include patients with active TED, young mothers unresponsive to repeated courses of thionamides, and children.
Postoperative complications include hypocalcaemia, recurrent laryngeal nerve injury, postoperative bleeding and complications of general anaesthesia.
| S TUDY AIMS AND ME THODS
The study was intended to look at the distribution, management and outcomes of patients with hyperthyroidism attending a typical secondary care endocrine clinic.
It is a retrospective longitudinal study of 442 patients who were All patients were treated with thionamides for a minimum 6-month period, and up to 2 years until normalisation of TSH was achieved. This was followed by a variable wean off period, and we defined a complete remission (or biochemical cure) as a normalised TFT for at least 6 months after complete cessation of drug treatment. A second course of treatment was offered to patients who relapsed, but this decision was often individualised, depending on circumstance, aetiology and patient preference.
Patients who subsequently still relapsed were generally referred for radioiodine therapy or much less commonly for thyroidectomy. with thyroid illness some patients may have received treatments in the past, prior to referral to our clinic. For the purpose of the study analysis, the duration of treatment was considered from the time of attendance to our clinic. One patient, for example, had been on longterm thionamide treatment for several years (1995) prior to referral, and this was highlighted in the free-text column.
| RE SULTS
As expected, females accounted for the majority (75%) of the population studied. The mean age at time of diagnosis was 52.6 ± 17.1 years (range 17-91 years).
The mean duration of treatment with thionamides in the cohort was 295 days. Of these, only a small proportion (2.5%) had to stop treatment due to side effects (Table 2) . Remission rates with drug treatment were better in patients with GD (43%), than in those with MNG (19%) and toxic nodule (25%) ( Table 3 ).
A total of 122 patients (28%) received radioiodine treatment.
Most patients were considered for radioiodine treatment following a relapse within 6 months of cessation of a second course of thionamide treatment. Other reasons included personal preference, high TRAB or drug side effects. A total of 18 subjects (15%) required a 2nd dose of radioiodine treatment.
A total of 61 patients (50%) developed permanent hypothyroidism within 6 months of radioiodine therapy and required thyroxine replacement therapy. As shown in Table 4 , subjects with GD showed a higher incidence of postradioiodine hypothyroidism than those with MNG or toxic nodule.
Eight patients underwent surgery, of whom six had GD and two amiodarone induced thyroid disease.
| D ISCUSS I ON
Hyperthyroidism has multiple aetiologies, manifestations and treatment options. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical comorbidities, patient preference and personal values and physician experience.
The majority of our patients were treated with thionamides in the first instance, followed by radioiodine therapy in cases of relapse despite a second course of drug treatment. Patients who had toxic MNG or toxic nodule were generally considered for radioiodine at an earlier stage than those with GD. This is supported by the better remission rates on drug treatment seen in GD compared with MNG or toxic nodule in our series (Table 3) , and which are similar to those from other studies. 3 We used CMZ in preference to PTU, and we employed a dose titration method rather than a block and replace regime. The former has a more favourable side effect profile. 11 We recorded significant side effects in only 2.5% of the cohort, and these were recorded in patients in whom drug treatments had to be changed or withdrawn, explaining the relatively low incidence.
Current guidelines recommend a mean radioiodine dose of 370-555 MBq to achieve a biochemical remission. Most of our patients received a standard dose of 550 MBq as although lower fixed doses (185 MBq) are associated with a lower incidence of hypothyroidism, cure rates are extremely low. 12 In our series, postradioiodine hypothyroidism was by far commoner in patients with GD compared to MNG or toxic nodule (Table 4) , encouraging early use of this treatment modality in the latter groups, whilst appropriately informing respective patients on risk of hypothyroidism.
These rates are also comparable to those from a long-term study on radioiodine treatment. benefits and risks of available treatment options and to help guide patients on often difficult treatment choices. In our opinion, this study should encourage the use of accurate record keeping and collection of real world data, facilitating the conduction of now mandatory specialist peer reviews in secondary care endocrine clinics.
| CON CLUS IONS
ACK N OWLED G EM ENT
The authors thank the local audit department for assistance in data collection as well as the local endocrinology department for their moral support.
CO N FLI C T O F I NTE R E S T
Nothing to declare.
AUTH O R S CO NTR I B UTI O N S
SYS is involved in data analysis and writing of manuscript. CL did the literature review. DVC instigated the idea of work, collected the data over the years and edited the manuscript in line with reviewer and editor comments. All authors approved the final version.
DATA ACCE SS I B I LIT Y
All data are provided in full in the results section of this paper.
E TH I C A L S TATEM ENT
This was not sought as the work was part of a long-term audit programme registered with the Local audit department. Patient data were recorded on a secure hospital network and anonymised at the time of analysis.
O RCI D
Sing Yang Sim http://orcid.org/0000-0003-1261-0407
